{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:16:01Z","timestamp":1790345761748,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Angiogenesis constitutes a critical rate-limiting determinant of tumor progression in breast cancer (BC). Resistance to conventional anti-angiogenic therapies in BC highlights an unmet need to identify upstream molecular regulators coordinating malignant cell plasticity and vascular remodeling. Lemur tail kinase 3 (LMTK3) is a well-established oncogenic kinase; however, its specific role within the tumor angiogenic microenvironment remains undefined. Here, we identify LMTK3 as a context-dependent driver of angiogenesis through a mesenchymal-epithelial transition (MET) program. By integrating single-cell RNA sequencing with functional validation, we uncover a \u2018Simpson\u2019s paradox\u2019 (where a correlation present in different groups disappears or reverses when combined): In mesenchymal-like triple-negative breast cancer (TNBC), LMTK3 promotes a pro-angiogenic, \u2018partial EMT\u2019 (p-EMT) state characterized by sustained ERK signaling and elevated secretion of angiogenic factors, including angiogenin. Conversely, in luminal-like cells, LMTK3 enforces a hyperepithelialized state that suppresses angiogenic phenotypes. Consequently, LMTK3 emerges as a central regulator of angiogenic plasticity, and its targeted inhibition offers a promising strategy to abrogate the pro-angiogenic p-EMT state and promote vascular normalization in TNBC.<\/jats:p>","DOI":"10.1038\/s41417-026-01001-2","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:27:49Z","timestamp":1769160469000},"page":"730-735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["LMTK3 regulates breast cancer angiogenesis via a context-dependent mesenchymal-epithelial transition program"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-2490","authenticated-orcid":false,"given":"Jian","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-6080","authenticated-orcid":false,"given":"Xiaoyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysa","family":"Filippopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Shirazi Nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xidong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijin","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4417-2707","authenticated-orcid":false,"given":"Georgios","family":"Giamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"1001_CR1","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477\u201395.","journal-title":"CA Cancer J Clin"},{"key":"1001_CR2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-023-01487-5","volume":"16","author":"M Niu","year":"2023","unstructured":"Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, et al. Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023;16:94.","journal-title":"J Hematol Oncol"},{"key":"1001_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nm.2351","volume":"17","author":"G Giamas","year":"2011","unstructured":"Giamas G, Filipovi\u0107 A, Jacob J, Messier W, Zhang H, Yang D, et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med. 2011;17:715\u20139.","journal-title":"Nat Med"},{"key":"1001_CR4","doi-asserted-by":"publisher","first-page":"46.","DOI":"10.1126\/sciadv.abc3099","volume":"6","author":"A Ditsiou","year":"2020","unstructured":"Ditsiou A, Cilibrasi C, Simigdala N, Papakyriakou A, Milton-Harris L, Vella V. The structure-function relationship of oncogenic LMTK3. Sci Adv. 2020;6:46.","journal-title":"Sci Adv"},{"key":"1001_CR5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.celrep.2015.06.073","volume":"12","author":"Y Xu","year":"2015","unstructured":"Xu Y, Zhang H, Nguyen VT, Angelopoulos N, Nunes J, Reid A, et al. LMTK3 represses tumor suppressor-like genes through chromatin remodeling in breast cancer. Cell Rep. 2015;12:837\u201349.","journal-title":"Cell Rep"},{"key":"1001_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2015.12.026","volume":"372","author":"J Jacob","year":"2016","unstructured":"Jacob J, Favicchio R, Karimian N, Mehrabi M, Harding V, Castellano L, et al. LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5. Cancer Lett. 2016;372:137\u201346.","journal-title":"Cancer Lett"},{"key":"1001_CR7","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/jjco\/hyu113","volume":"44","author":"T Asano","year":"2014","unstructured":"Asano T, Sato S, Yoshimoto N, Endo Y, Hato Y, Dong Y, et al. High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor \u03b1-positive breast cancer patients. Jpn J Clin Oncol. 2014;44:889\u201397.","journal-title":"Jpn J Clin Oncol"},{"key":"1001_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10549-011-1622-z","volume":"132","author":"J Stebbing","year":"2012","unstructured":"Stebbing J, Filipovic A, Ellis IO, Green AR, D\u2019Silva TR, Lenz HJ, et al. LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat. 2012;132:537\u201344.","journal-title":"Breast Cancer Res Treat"},{"key":"1001_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02346-2","volume":"24","author":"M Samuels","year":"2025","unstructured":"Samuels M, Karakostas C, Besta S, Lauer Betr\u00e1n A, Tsilingiri K, Turner C, et al. LMTK3 regulation of EV biogenesis and cargo sorting promotes tumour growth by reducing monocyte infiltration and driving pro-tumourigenic macrophage polarisation in breast cancer. Mol Cancer. 2025;24:149.","journal-title":"Mol Cancer"},{"key":"1001_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01345-3","volume":"20","author":"C Cilibrasi","year":"2021","unstructured":"Cilibrasi C, Ditsiou A, Papakyriakou A, Mavridis G, Eravci M, Stebbing J, et al. LMTK3 inhibition affects microtubule stability. Mol Cancer. 2021;20:53.","journal-title":"Mol Cancer"},{"key":"1001_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02331-9","volume":"24","author":"C Landragin","year":"2025","unstructured":"Landragin C, Saichi M, Laisn\u00e9 M, Durand A, Prompsy P, Leclere R, et al. Epigenomic disorder and partial EMT impair luminal progenitor integrity in Brca1-associated breast tumorigenesis. Mol Cancer. 2025;24:127.","journal-title":"Mol Cancer"},{"key":"1001_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.10.004","volume":"97","author":"X Wang","year":"2023","unstructured":"Wang X, Eichhorn PJA, Thiery JP. TGF-\u03b2, EMT, and resistance to anti-cancer treatment. Semin Cancer Biol. 2023;97:1\u201311.","journal-title":"Semin Cancer Biol"},{"key":"1001_CR13","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.devcel.2021.11.006","volume":"56","author":"F L\u00fc\u00f6nd","year":"2021","unstructured":"L\u00fc\u00f6nd F, Sugiyama N, Bill R, Bornes L, Hager C, Tang F, et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev Cell. 2021;56:3203\u201321.e11.","journal-title":"Dev Cell"},{"key":"1001_CR14","doi-asserted-by":"publisher","first-page":"165372","DOI":"10.1016\/j.bbadis.2018.12.023","volume":"1867","author":"F Wendler","year":"2021","unstructured":"Wendler F, Purice TM, Simon T, Stebbing J, Giamas G. The LMTK-family of kinases: Emerging important players in cell physiology and pathogenesis. Biochim Biophys Acta Mol Basis Dis. 2021;1867:165372.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1001_CR15","doi-asserted-by":"publisher","first-page":"19.","DOI":"10.3390\/ijms241914815","volume":"24","author":"J Lu","year":"2023","unstructured":"Lu J, Kornmann M, Traub B. Role of epithelial to mesenchymal transition in colorectal cancer. Int J Mol Sci. 2023;24:19.","journal-title":"Int J Mol Sci"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01001-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01001-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01001-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:05:35Z","timestamp":1785517535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01001-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01001-2","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GG was the editor-in-chief of Cancer Gene Therapy until 31\/12\/2025. This manuscript went through a standard external peer review process. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}